TY - JOUR
T1 - Successful intra-class switching among IL-17 antagonists
T2 - a multicentre, multinational, retrospective study
AU - Gasslitter, Irina
AU - Kirsten, Natalia
AU - Augustin, Matthias
AU - Torz, Kaspar
AU - Mrowietz, Ulrich
AU - Eyerich, Kilian
AU - Puig, Lluís
AU - Hoetzenecker, Wolfram
AU - Schütz-Bergmayr, Martina
AU - Weger, Wolfgang
AU - Wolf, Peter
AU - Reider, Norbert
AU - Ratzinger, Gudrun
AU - Papageorgiou, Karolina
AU - Meier, Thomas O.
AU - Maul, Julia Tatjana
AU - Anzengruber, Florian
AU - Navarini, Alexander A.
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/7/5
Y1 - 2019/7/5
N2 - IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.
AB - IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.
KW - Brodalumab
KW - IL-17
KW - IL-17 receptor blocker
KW - IL-17A
KW - Interleukin-17
KW - Ixekizumab
KW - Secukinumab
UR - http://www.scopus.com/inward/record.url?scp=85062953950&partnerID=8YFLogxK
U2 - 10.1007/s00403-019-01907-y
DO - 10.1007/s00403-019-01907-y
M3 - Article
C2 - 30879102
AN - SCOPUS:85062953950
SN - 0340-3696
VL - 311
SP - 421
EP - 424
JO - Archives of Dermatological Research
JF - Archives of Dermatological Research
IS - 5
ER -